Our Pricing

Switch to Wegovy at Cured Pharmacy & Save from £79.00

Looking to switch to Wegovy UK online pharmacy with transparent pricing and expert clinical support? At Cured Pharmacy, you'll access genuine UK-licensed Wegovy pens from £79.00, with a free online consultation completed in under 3 minutes by our UK-registered prescribers. Whether you're transitioning from another GLP-1 treatment or starting your weight management journey, our superintendent pharmacist Tarun Kumar and clinical team ensure safe, discreet service every step of the way.

Why Switch to Wegovy for Weight Management

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Unlike older weight loss medications, semaglutide mimics a natural gut hormone that regulates appetite and food intake, helping patients achieve sustained weight reduction when combined with lifestyle modifications.

The STEP 1 clinical trial demonstrated that patients using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents one of the most significant weight loss outcomes observed in pharmaceutical trials, with 83.5% of participants losing at least 5% of their baseline body weight [1]. These results have positioned Wegovy as a leading option for patients who haven't achieved adequate results with diet and exercise alone.

Many patients switch to Wegovy from daily injectable treatments like Saxenda (liraglutide) due to the convenience of once-weekly dosing and superior efficacy data. The simplified dosing schedule improves adherence and fits more naturally into busy lifestyles, whilst the gradual dose escalation protocol minimises gastrointestinal side effects commonly associated with GLP-1 therapies [2].

How to Switch to Wegovy UK Online Pharmacy Safely

Switching from another weight loss medication to Wegovy requires clinical assessment by a UK-registered prescriber to ensure the transition is safe and appropriate for your individual circumstances. At Cured Pharmacy, our online consultation takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any previous treatments you've used.

If you're currently taking another GLP-1 medication such as Saxenda or Ozempic, your prescriber will determine the appropriate starting dose of Wegovy based on your current regimen. The standard Wegovy initiation protocol begins at 0.25mg weekly for four weeks, then escalates gradually to the maintenance dose of 2.4mg over 16-20 weeks [2]. This stepwise approach allows your body to adjust and reduces the likelihood of nausea and other gastrointestinal symptoms.

For patients switching from non-GLP-1 treatments like Orlistat or Mysimba, the transition is typically more straightforward, though a washout period may be recommended depending on your specific medication. Your UK prescriber will provide clear guidance on timing, what to expect during the first few weeks, and how to monitor your progress effectively.

What to Expect During Your First Month on Wegovy

The initial 0.25mg dose is intentionally sub-therapeutic, designed to help your digestive system adapt to semaglutide rather than produce significant weight loss. Most patients notice reduced appetite and earlier satiety during weeks 2-4, with measurable weight loss typically beginning during the dose escalation phase. Mild nausea, occasional constipation, and reduced hunger are the most commonly reported effects during the first month, and these generally resolve as your body adjusts [2].

Wegovy Pricing and What's Included at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00 per pen, with transparent upfront pricing displayed before you begin your consultation. Unlike some providers who reveal costs only after assessment, we believe patients deserve clarity from the outset. All prices include your medication, free online consultation with a UK prescriber, and discreet delivery to your chosen address.

Your Wegovy prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) and delivered in plain, unmarked packaging for complete privacy. We source all medications directly from UK-licensed wholesalers, ensuring every pen meets MHRA standards and comes with full patient information leaflets. Our clinical team remains available for follow-up queries throughout your treatment, with no hidden consultation fees or subscription charges.

We also offer a lowest price guarantee across the UK market. If you find genuine UK-licensed Wegovy at a lower price from another registered pharmacy, we'll match it. This commitment ensures you receive the best possible value without compromising on clinical safety or pharmaceutical standards.

Comparing Wegovy to Other Weight Loss Treatments

The UK weight loss treatment landscape has expanded significantly in recent years, with several prescription options now available beyond traditional lifestyle interventions. Understanding the differences between these medications helps patients and prescribers select the most appropriate therapy based on individual goals, medical history, and lifestyle factors.

Wegovy (semaglutide) and Mounjaro (tirzepatide) represent the latest generation of injectable GLP-1 receptor agonists, both offering once-weekly dosing and robust clinical efficacy data. Saxenda (liraglutide), whilst also a GLP-1 agonist, requires daily injections and generally produces more modest weight loss compared to the newer weekly options [3]. Oral medications like Orlistat work through a different mechanism entirely, blocking fat absorption in the gut rather than regulating appetite hormones, and typically result in smaller absolute weight reductions [4].

Your choice between these options depends on multiple factors including your BMI, previous treatment responses, tolerance for injections, and specific health conditions. A UK prescriber will consider all these elements during your consultation to recommend the treatment most likely to help you achieve sustainable results.

Clinical Efficacy: What the Trial Data Shows

Direct comparison trials have demonstrated that semaglutide 2.4mg (Wegovy) produces superior weight loss compared to liraglutide 3mg (Saxenda), with average reductions of 14.9% versus 7.8% respectively over similar timeframes [1][3]. Tirzepatide (Mounjaro) has shown even greater efficacy in the SURMOUNT trials, with average weight reductions up to 20.9% at the highest dose, though individual responses vary considerably [5]. These figures represent average outcomes in controlled clinical settings; real-world results depend heavily on adherence to lifestyle modifications alongside medication use.

Who Can Switch to Wegovy: Eligibility Criteria

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. These criteria align with NICE guidelines for pharmacological weight management and ensure the medication is prescribed to patients most likely to benefit.

Certain medical conditions may preclude Wegovy use or require additional monitoring. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide due to theoretical thyroid risks observed in rodent studies [2]. Active gallbladder disease, severe gastrointestinal disorders, and a history of pancreatitis also require careful evaluation before prescribing.

During your online consultation at Cured Pharmacy, our UK prescribers will review your complete medical history, current medications, and any contraindications to ensure Wegovy is safe and appropriate for you. This assessment is mandatory under UK pharmacy regulations and protects patient safety whilst ensuring optimal treatment outcomes.

Switching from Type 2 Diabetes Medications

Patients currently taking semaglutide for type 2 diabetes (Ozempic) may be eligible to switch to the higher-dose Wegovy formulation for weight management, subject to prescriber approval. Whilst both contain the same active ingredient, Wegovy is dosed higher (up to 2.4mg weekly) compared to Ozempic's maximum 1mg dose for diabetes. Your prescriber will coordinate any transition to ensure continuous glycaemic control and appropriate dose titration.

Managing Side Effects When You Switch to Wegovy

Gastrointestinal side effects are the most commonly reported adverse events with Wegovy, affecting approximately 44% of patients in clinical trials [1]. Nausea, diarrhoea, constipation, and abdominal discomfort typically occur during dose escalation phases and tend to diminish over time as your body adapts to semaglutide. These effects are generally mild to moderate in severity and rarely lead to treatment discontinuation when managed appropriately.

Practical strategies to minimise side effects include eating smaller, more frequent meals, avoiding high-fat foods that may exacerbate nausea, staying well-hydrated, and taking your injection on the same day each week. If you experience persistent or severe symptoms, your prescriber may recommend pausing dose escalation temporarily to allow better tolerance before progressing to higher strengths.

Rare but serious adverse events include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients also taking other diabetes medications). Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment and can adjust your prescription or provide guidance if side effects become concerning.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Novo Nordisk Limited. https://www.medicines.org.uk/emc/product/13799
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications alongside medication use. Wegovy is a prescription-only medicine licensed by the MHRA for chronic weight management in eligible adults.